Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib
- Status
- COMPLETED
- Phase
- PHASE2
MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- Status
- UNKNOWN
- Phase
- N/A
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
- Status
- RECRUITING
- Phase
- PHASE2
First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting
- Status
- UNKNOWN
- Phase
- N/A
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3